ClinicalTrials.gg
Not yet recruitingNCT07927972SPIBA-101Updated Nov 10, 2026

Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome

A Phase 1 interventional study of Elamipretide in Barth Syndrome, sponsored by Stealth BioTherapeutics Inc.. Not yet recruiting. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Stealth BioTherapeutics Inc. · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Sex
Male
01

Study summary

This Phase 1, open-label trial will enroll approximately 6 subjects who have BTHS weighing between 7 and 30 kg. Subjects will receive a weight-based dose of elamipretide daily via SC injection for 4 weeks. PK samples will be collected on Day 1 and at week 4 to determine PK profile in BTHS patients weighing between 7 and 30kg.

Read the detailed description

In this Phase 1, open-label trial to evaluate the PK, safety, and tolerability of elamipretide, approximately 6 pediatric subjects with genetically confirmed BTHS weighing between 7 and 30 kg will be enrolled to receive daily dosing via SC injection for 4 weeks.

To characterize the PK of elamipretide, PK sampling will be conducted at Day 1 and Week 4. The study is intended to characterize PK and safety across a broader range of body weights that haven't been studied in prior trials.

02

Conditions studied

  • Barth Syndrome

Keywords

  • Barth Syndrome
  • Elamipretide
03

In context

Lead sponsor

Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide signed form (ICF) prior to participation in any trial-related procedures. If applicable, informed consent in writing from parent(s) or legally-acceptable representative(s) and, informed assent from subject (if age appropriate according to local requirements) should be provided.
  2. Agrees to adhere to the trial requirements for the length of the trial.
  3. Must have genetically confirmed Barth Syndrome (pathogenic variant in the TAZ gene)
  4. Male aged ≥ 1 year and weighing between 7 and 30 kg at time of the Baseline Visit
  5. For subjects with a medical history of cardiomyopathy, must be on a stable regimen (unchanged and constant) of background heart failure medications for at least 3 months prior to the Screening Visit.
  6. Able to administer IMP or have an appropriate designee who can administer the IMP (i.e., a capable family member or a caregiver).

Exclusion criteria

Exclusion Criteria:

  1. History of solid organ transplant, except successful cardiac transplantation >12 months prior to Screening, if, in the opinion of the Investigator, there is no evidence of organ rejection and post-transplant pharmacotherapy, the subject is stable, and participation in the trial does not pose additional safety risk.
  2. Current placement on the waiting list for heart transplantation.
  3. Hospitalization for heart failure within 6 months prior to the Screening/Baseline Visit
  4. Any disease or medical condition that in the opinion of the Investigator would prevent the subject from successfully participating in the trial and reliably completing the assessments or might confound trial results.
  5. of \< 30 mL/min at the Screening Visit (for purposes of Screening, eGFR can be confirmed locally at the clinical site. Historical values within 3 months prior to Screening can be accepted).
  6. Active or any other cancer from which the subject has been cancer-free for \< 2 years. Localized squamous or non-invasive basal cell skin carcinomas are allowed, if appropriately treated prior to Screening/Baseline.
  7. Participation in other drug or device clinical trials within 30 days or 5 half-lives (whichever is longer) of Screening/Baseline; or is currently enrolled in a non-interventional clinical trial that, in the opinion of the Investigator, may be potentially confounding to the results of the current trial. NOTE: Subjects currently treated with elamipretide through an EAP are eligible to participate in the SPIBA-101 study.
  8. History of allergic reaction to the IMP or any of its components.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Elamipretide

    SC injection daily

    Drug: Elamipretide

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration of elamipretide and its metabolites

    Characterization of the maximum plasma concentration (Cmax) of elamipretide and its metabolites utilizing population PK modeling.

    Time frame: 24 hours

  2. Area under the plasma concentration time curve from 0 to 24 hours

    Characterization of the area under the plasma concentration time curve from 0 to 24 hours of elamipretide and its metabolites (AUC0-24) utilizing population PK modeling.

    Time frame: 24 hours

Secondary outcomes

  1. Safety Assessments: Adverse Events and Serious Adverse Events

    The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) from baseline through 4 weeks. Report the # of subjects with adverse events and incidence and severity of such adverse events (AEs)

    Time frame: 4 weeks

  2. Change from baseline of Clinical Hematology

    Change from baseline in clinical hematology utilizing descriptive statistics of change relative to baseline and shift tables to show number of subjects who are low, normal, high at baseline verses week 4.

    Time frame: 4 Weeks

  3. Change in Clinical Chemistry from Baseline

    Change from baseline in Clinical Chemistry utilizing descriptive statistics of change relative to baseline and shift tables to show number of subjects who are low, normal, high at baseline verses week 4.

    Time frame: 4 weeks

  4. Change in 12 Lead Electrocardiogram ECG QT Interval from Baseline

    Change in findings of 12 Lead Electrocardiogram ECG QT Interval from baseline

    Time frame: 4 weeks

  5. Change in 12 Lead Electrocardiogram ECG heart rate from Baseline

    Change in 12 Lead Electrocardiogram ECG heart Rate from Baseline

    Time frame: 4 weeks

  6. Change in Vital Signs from Baseline: Temperature

    Change in temperature measure (Fahrenheit or Celsius) from baseline to week 4

    Time frame: 4 weeks

  7. Change in Vital Signs from Baseline: Respiratory Rate

    Change in respiratory rate (breaths per minute) from baseline to week 4

    Time frame: 4 weeks

  8. Change in Vital Signs from Baseline: Blood Pressure

    Change in resting (5 minutes) Blood Pressure (mm Hg) from baseline to week 4

    Time frame: 4 weeks

  9. Change in Vital Signs from Baseline: heart rate

    Change in Heart Rate (beats per minute) from baseline to week 4

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 10, 2026
StartEst.
Nov 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07927972
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Rekha Sathyanarayana
Contact
rekha.sathyanarayana@stealthbt.com
617-762-2579

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion